Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)

Inclusion Criteria

• Age/Gender: males and females aged >20 to < 65 years (at the time of obtaining consent).
• Positive cases in whom blood specific IgE antibody quantification against cedar pollen showed class 2-6 in a health checkup conducted within the past 3 years.
• Cases who were diagnosed as patients with seasonal allergic conjunctivitis and were judged eligible as subjects of the said study by the investigator or co-investigator from the results of medical examination conducted on the day of the study or prior to it.
• Cases who gave consent on study participation of their own free will in writing, with understanding the contents of the said study.

Exclusion Criteria

• Cases with an ocular disease that requires treatment other than allergic conjunctivitis.
• Cases with an inflammatory ocular disease in the external/anterior part of the eye that may affect drug efficacy evaluation.
• Cases with a respiratory disease such as bronchial asthma other than allergic rhinitis.
• Cases with past history of anaphylaxis.
• Cases with past history of hypersensitivity to olopatadine hydrochloride/tranilast.
• Cases undergoing immunotherapy (hyposensitization therapy; modulated therapy).
• Patients who are pregnant, lactating women, or may be pregnant, or cases wishing to be pregnant during the study period.
• Other cases who are judged ineligible for participation in the main study by the doctor in charge of the study.